Objectives: The aim of this study was to evaluate the cost-effectiveness of pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant treatment for locally advanced, inflammatory, or early stage breast cancers that overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian National Health System (SSN) perspective. MethOds: A six state Markov model was used to estimate outcomes and costs over a 50-year time horizon. Patients were assumed to receive standard neo-adjuvant therapy containing trastuzumab and docetaxel or the same regimen plus pertuzumab. Transition probabilities to progressive disease and death were based on total pathological complete response (pCR) rates observed in the NeoSphere study. A second analysis was carried out in which progression-free survival (PFS) was directly modelled on observed data. Expected survival was adjusted by utility weights for health states derived from literature. Direct medical unit costs were collected from official and published Italian sources. Costs and health gains were discounted at an annual 3% rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncertainty. Results: Pertuzumab combination was associated with increased QALYs and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of pertuzumab was the primary contributor to the difference in costs, partially offset through the prevention of relapse and worsening. The estimated ICERs range between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very high probability of being cost effective relative to standard regimen for a WTP threshold of € 40,000 per QALY gained. cOnclusiOns: Breast cancer with HER2 overexpression is associated with increased tumour aggressiveness, higher rates of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combination with trastuzumab and docetaxel is expected to be more effective (increased probability to reach higher pCR rate and longer PFS) than standard regimen, at a favourable cost per QALY gained. While survival rates in colorectal cancer are improving globally, the UK continues to lag behind other major economies. Recent evidence demonstrates that cetuximab can result in significant life extension when added to chemotherapy as a first line treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is funded in Wales mainly through Individual Patient Treatment Requests which are increasing in number due to the rising demand from both patients and physicians. An evidence submission was submitted to AWMSG to highlight this clinical benefit and assess the cost effectiveness of cetuximab. MethOds: An economic model was developed to assess the cost effectiveness of cetuximab in the management of unresectable RAS wt metastatic colorectal cancer in comparison to comparators available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small population of patients with metastases confined to the liver who may subsequently be eligible for curative resection after treatment with cetuximab plus chemotherapy. The time horizon is 10 years and the discount rate applied to both outcomes and costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in all analyses and the dose was set to fortnightly dosing as typically prescribed in Wales. Results: Economic analyses estimated an incremental cost effectiveness ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI alone. cOnclusiOns: These analyses demonstrate that cetuximab is a cost effective treatment and a good use of NHS Wales resources through stratification of RAS wild type patients who are likely to respond to treatment and offer patients a life-extending treatment option.
Objectives: The aim of this study was to evaluate the cost-effectiveness of pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant treatment for locally advanced, inflammatory, or early stage breast cancers that overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian National Health System (SSN) perspective. MethOds: A six state Markov model was used to estimate outcomes and costs over a 50-year time horizon. Patients were assumed to receive standard neo-adjuvant therapy containing trastuzumab and docetaxel or the same regimen plus pertuzumab. Transition probabilities to progressive disease and death were based on total pathological complete response (pCR) rates observed in the NeoSphere study. A second analysis was carried out in which progression-free survival (PFS) was directly modelled on observed data. Expected survival was adjusted by utility weights for health states derived from literature. Direct medical unit costs were collected from official and published Italian sources. Costs and health gains were discounted at an annual 3% rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncertainty. Results: Pertuzumab combination was associated with increased QALYs and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of pertuzumab was the primary contributor to the difference in costs, partially offset through the prevention of relapse and worsening. The estimated ICERs range between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very high probability of being cost effective relative to standard regimen for a WTP threshold of € 40,000 per QALY gained. cOnclusiOns: Breast cancer with HER2 overexpression is associated with increased tumour aggressiveness, higher rates of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combination with trastuzumab and docetaxel is expected to be more effective (increased probability to reach higher pCR rate and longer PFS) than standard regimen, at a favourable cost per QALY gained. While survival rates in colorectal cancer are improving globally, the UK continues to lag behind other major economies. Recent evidence demonstrates that cetuximab can result in significant life extension when added to chemotherapy as a first line treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is funded in Wales mainly through Individual Patient Treatment Requests which are increasing in number due to the rising demand from both patients and physicians. An evidence submission was submitted to AWMSG to highlight this clinical benefit and assess the cost effectiveness of cetuximab. MethOds: An economic model was developed to assess the cost effectiveness of cetuximab in the management of unresectable RAS wt metastatic colorectal cancer in comparison to comparators available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small population of patients with metastases confined to the liver who may subsequently be eligible for curative resection after treatment with cetuximab plus chemotherapy. The time horizon is 10 years and the discount rate applied to both outcomes and costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in all analyses and the dose was set to fortnightly dosing as typically prescribed in Wales. Results: Economic analyses estimated an incremental cost effectiveness ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI alone. cOnclusiOns: These analyses demonstrate that cetuximab is a cost effective treatment and a good use of NHS Wales resources through stratification of RAS wild type patients who are likely to respond to treatment and offer patients a life-extending treatment option. bAckgROund: In September 2014 the European Commission granted marketing authorisation for idelalisib with rituximab (I+R) for the treatment of chronic lymphocytic leukaemia (CLL) in previously treated patients and treatment-naïve patients with a 17p deletion or TP53mutation. Objectives: This study evaluated the cost effectiveness of I+R in previously-treated patients according to their eligibility for chemo-immunotherapy in England and Wales. MethOds: A 5-state Markov model was constructed from a National Health Service (NHS) perspective over a lifetime horizon. Study 116 contained 220 patients for whom chemo-immunotherapy was unsuitable owing to poor previous response to such treatment, the presence of 17p deletion or TP53mutation, or their fitness, randomised 1:1 to I+R (intervention) or rituximab with placebo (comparator). Intervention-arm data from Study 116 were used to inform the effectiveness of I+R in terms of response, time on treatment, progression-free and overall survival. Comparatorarm data from Study 116 were used to inform the effectiveness of (i) rituximab monotherapy, and using further assumptions, (ii) ofatumumab monotherapy and Costs included in the model were drugs & administration, post-treatment resource use, toxicity management and indirect treatment costs. Cost effectiveness was evaluated using the Gamma distribution for Overall Survival(OS), Weibull for Progression Free Survival(PFS), response duration and, toxicity time. Health state utilities were applied to each component and aggregated. In base-case analysis, 3% discounting was applied for both benefits and costs. Deterministic sensitivity analysis was used to evaluate sensitivity of the key variables. Results: OS based on Gamma extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group for a difference of 2.87 months. Mean time without progressive disease was 4.68 months for eribulin and 3.96 months for TPC for a difference of 0.72 months. The Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC group for a mean incremental improvement of 0.13 years. Treatment costs were NTD 351,875 for eribulin and NTD 113,552 for TPC for a difference of NTD 238,323. In base-case analysis, the ICER with discounting was NTD 1,823,482. Survival time was most sensitive variables on the ICER in this CEA. cOnclusiOns: With an ICER of NTD 1,823,482 compared to TPC, eribulin was found to be cost-effective in third and later line MBC population in Taiwan. Given the limited number of effective therapeutic options available to these patients, eribulin represents a valid option for optimizing treatment pathways. Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) in Best Efficacy Subgroup (BES) patients previously treated with oxaliplatino compared to FOLFIRI. MethOds: A post-hoc analysis of the VELOUR clinical trial revealed an improvement of aflibercept efficacy in a specific subgroup. BES was composed by patients with performance status (PS) 0 with any number of metastatic sites or PS 1 with < 2 metastatic sites, exclusive of adjuvant fast relapsers. A Markov model with 3 health states (stable disease, progression and death) was used to estimate lifetime costs and outcomes (2-weeks cycle duration). Transition from stable disease to progression implied the interruption of second-line treatment and administration of a third-line chemotherapy (72%) or best supportive care (28%). According to the National Health System (NHS) perspective only direct costs were considered. Cost estimation (€ , 2015) included pharmaceutical and administration cost, adverse event management and hospital and medical visits consumption. Ex-factory price with mandatory deduction was applied for drug cost estimation. Costs and outcomes were 3% annually discounted. Sensitivity analyses (SA) were performed. Results: Administration of aflibercept + FOLFIRI as second-line treatment on BES was more effective than FOLFIRI, yielding 1.92 LYG (23 life-months gained) compared to 1.55 LYG (18.6 months). Aflibercept + FOLFIRI accounted a total cost of € 40,449, compared to € 25,698 estimated for FOLFIRI. The incremental cost-effectiveness analysis provided a € 33,373/LYG ratio for aflibercept in combination with FOLFIRI versus FOLFIRI for BES. SA results confirmed the model robustness. cOnclusiOns: According to a post-hoc analysis, aflibercept in combination with FOLFIRI could increase overall survival versus FOLFIRI on BES. Aflibercept + FOLFIRI could be an efficient strategy for second-line treatment in specific mCRC patients for the Spanish NHS. Objectives: The problem of anthracycline-induced clinical heart failure is an important public health concern as it may not be seen for many years and remains a life-long threat. We performed a cost-effectiveness analysis of the cardioprotective effect of Dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy in México. MethOds: A decision tree model was developed in order to compare dexrazoxane with no treating. The time horizon was one year. The main data for dexrazoxane efficacy (surgery requirement and functional loss) was obtained from two open label non-comparative studies. Main costs taken into account were the drug costs, administration and monitoring and surgical costs. Results: Dexrazoxane may lead to important savings for the Mexican public health system when it is compared to no treating. The results derived from the model indicate that Dexrazoxane is associated with less cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05) which represent a saving of 200,000 USD per patient treated. Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions. cOnclusiOns: Dexrazoxane is a dominant alternative vs no treating since it significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen at a lower cost than no treating Objectives: Regorafenib is indicated in the treatment of locally advanced, nonresectable gastrointestinal stromal tumors (GIST) that did not respond to prior imatinib mesylate and sunitinib malate. The objective of this study is to evaluate the cost-effectiveness of regorafenib compared to standard care, since no other third line treatment is available, in metastatic/inoperable GISTs in Turkey. MethOds: A Markov model taking transitions of patients between three health states of "progression-free", "progressed" or "dead" was adapted to Turkish settings. Clinical transition inputs between health states and safety data were mainly derived from GRID study. Economic inputs were based on the experts' opinion addressing local treatments, routine monitoring and adverse event management algorithms. The incremental cost-effectiveness ratios (ICER) were calculated per quality adjusted life years (QALY) gained. Analyses were conducted from the Turkish Payer Social Security Institution perspective. All costs were calculated in Turkish Liras (TL). The cost effectiveness (CE) threshold defined by World Health Organization (WHO) for developing countries as ICER 1-3 fold of annual income per capita was calculated based on the Turkish 2014 annual income per capita of 10,404.00 USD and converted to TL using TL/USD currency rate of 2.28 (end of 2014). Results: Total costs associated with regorafenib and standard care are 22,902 and 1,692 TL, respectively. On the other hand, QALYs gained with regorafenib (2.714) was almost twice compared to standard care (1.402), with an ICER of 16,481 TL/year. This additional cost of treatment is below the lower margin of CE threshold that was 23,721.00 TL. cOnclusiOns: Regorafenib is a costeffective treatment option in metastatic/inoperable GISTs in Turkey. Compared to standard care, the additional cost of treatment is below the CE threshold. Objectives: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that has demonstrated its efficacy in treating Gastrointestinal stromal tumor (GIST) patients who are no longer responded to imatinib 400mg/day. The purpose of this study is to evaluate the cost-effectiveness of sunitinib as a second-line treatment in patients with advanced GISTs in China from a third party payer's perspective. MethOds: A Markov model was developed to simulate disease progression and to determine cost and effectiveness outcomes over a 5-year time horizon. The different secondline treatment arms compared were sunitinib 50 mg/day (4 weeks on and 2 weeks off), imatinib 600 mg/day, imatinib 800 mg/day, and best supportive care (BSC). The probabilities of state transitions and utilities were obtained from previous published trials. Resource use and costs data were obtained from previous studies and public sources. A 3.5% annual discount rate after the first year was applied to both costs and outcomes. The incremental cost-effectiveness ratios (ICER) between treatment with sunitinib vs. other treatment options were calculated. Results: In the base case, treatment with sunitinib vs. imatinib 600 mg resulted in 0.744 PFLY gained, 0.423 LY gained and 0.398 QALYs gained at an incremental cost of RMB14,750. The ICER was RMB37,023 per QALY gained. Treatment with sunitinib was dominant compared with imatinib 800 mg, with lower costs and higher QALYs . Treatment with sunitinib vs BSC resulted in patients' benefits of 0.257 PFLY gained, 1.357 LY gained and 0.836 QALYs gained at an incremental cost of RMB106,889. The ICER was RMB127,801 per QALY gained. cOnclusiOns: Among patients with advanced GISTs who have failed imatinib 400mg/day as the first-line treatment, sunitinib provides greater clinical benefit than high-dose imatinib or BSC. In the Chinese setting, sunitinib is estimated to be either cost-saving or cost-effective compared with imatinib 800 mg, imatinib 600mg or BSC. Objectives: To assess the cost-effectiveness of ceritinib versus other therapies in the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) from the UK National Health Service (NHS) and Personal Social Service (PSS) perspective. MethOds: A partitioned survival model with three health states (progression-free, progressive, and death) was developed to compare ceritinib versus other treatments in patients with ALK+ NSCLC who were previously treated with chemotherapy (post-CT), or with an ALK inhibitor, regardless of prior chemotherapy (post-ALKi). The comparator arms included crizotinib, docetaxel, and pemetrexed in the post-CT population and best supportive care (BSC), docetaxel, and pemetrexed in the post-ALKi population. Progression-free survival and overall survival for ceritinib were estimated using the ASCEND-1 (NCT01283516), ASCEND-2 (NCT01685060), and ASCEND-3 (NCT01685138) trial data. Parametric models were used to extrapolate outcomes beyond the trial period. Survival data for comparators were obtained from published clinical trials. Drug acquisition, administration, medical and adverse event (AE) costs were obtained from publicly available databases. Utilities for health states and disutilities for AEs based on EQ-5D were derived from literature. Incremental costs per quality-adjusted life year (QALY) gained were estimated comparing ceritinib vs. each comparator. Univariate and probabilistic sensitivity analyses were performed. Results: Over 10 years, ceritinib was associated with 2.69 QALYs and total direct costs of £80,445 for post-CT population. The incremental cost per QALY was £30,536 comparing ceritinib vs. crizotinib, £44,847 vs. docetaxel, and £38,966 vs. pemetrexed. Among post-ALKi population, the QALY and total direct costs for ceritinib were 0.94 and £45,712 respectively. The incremental cost per QALY was £48,808 comparing ceritinib vs. BSC, £57,660 vs. docetaxel, and £40,145 vs. pemetrexed. Sensitivity analysis results were consistent with the basecase findings. cOnclusiOns: Based on the willingness-to-pay threshold for end-(iii) best supportive care (BSC). To compare I+R to steroids with rituximab (an alternative treatment for the patient group in Study 116) and to make exploratory comparisons to chemo-immunotherapies, curve fits to systematically-identified comparator trial data were made using a common-shape approach and adjustment for prognostic factors. Utility data and drug, medical resource, adverse event and terminal care costs were obtained from Study 116 EQ-5D surveys, published sources and clinical input. Results: Compared to (i) rituximab monotherapy, (ii) ofatumumab monotherapy and (iii) BSC, in patients ineligible for chemo-immunotherapy, the base case ICERs for I+R were (i) £21,224, (ii) £9,116 and (iii) £28,015 per QALY gained, respectively and inclusive of a simple price discount. Further comparisons provided ICERs ranging from £20,431 to £34,603. cOnclusiOns: I+R was shown to be cost effective in previously-treated patients ineligible for chemo-immunotherapy. Objectives: To evaluate the cost-effectiveness of ofatumumab plus chlorambucil (OChl) versus chlorambucil (Chl) for the first-line treatment of chronic lymphocytic leukemia (CLL) in patients not eligible for fludarabine-based therapy from the United Kingdom health care payer perspective. MethOds: A semi-Markov decision model was developed with a lifetime time horizon of 25 years and a 3-month cycle length. The COMPLEMENT-1 trial provided estimates of overall response rates (ORR), progression-free survival (PFS), overall survival (OS), safety data, and preprogression utility weights (EQ-5D). The number of patients in the "preprogression," "progressive disease," and "dead" health states at the end of each cycle was determined by parametric survival functions for PFS and OS. Long-term predictions for OS were guided by external data; the treatment effect observed in the trial was assumed not to continue beyond trial follow-up. Data from published literature and UK treatment practices and patterns were used to inform costs and utility in the postprogression health states. Incremental lifetime costs and quality-adjusted life-years (QALYs) were calculated. Results: The base-case incremental cost-effectiveness ratio (ICER) was £32,950 per QALY gained, with incremental discounted costs and QALYs of £10,492 and 0.32, respectively. Discount rate was 3.5% for both cost and outcomes. The probability of cost-effectiveness at a willingness-to-pay threshold of £30,000 per QALY was 43%. Univariate sensitivity analyses indicated that the proportion of patients who received active therapy after progression following first-line treatment (responders, active second-line treatment) had the largest influence on the ICER. However, none of the variables considered generated an ICER exceeding £38,000 per QALY gained. cOnclusiOns: The improved ORR, PFS, and OS for OChl compared with Chl translated to improved long-term health outcomes in the base-case analysis. The results were robust in a wide range of sensitivity analyses and did not exceed £38,000/QALY. Objectives: Idelalisib/ rituximab (IR) is licenced for the treatment of adults with CLL who either have received at least one previous therapy and as first line treatment for patients with del17p/TP53 mutations. Prior to the availability of IR, individuals in these patient groups received best supportive care (BSC). The clinical efficacy of the IR in these patient groups was demonstrated in a Phase III RCT ('study 116'). The cost-effectiveness of IR in this patient group is unknown. MethOds: A response stratified partitioned survival model (overall survival -OS, progression free survival -PFS) was developed to estimate the lifetime costs and benefits associated with IR and BSC for a Scottish NHS perspective using a lifetime horizon and monthly cycles. OS, PFS, overall response (OR) and resource use data was taken directly from study 116. Information from study 116 was used as far as possible for patients with del17p / TP53 mutations, with expert opinion used where necessary. Utility scores were taken from published sources. Unit/drug costs were taken from national databases and discounted at 3.5% p.a. Probabilistic and deterministic sensitivity analyses were conducted to estimate the confidence around the results. Outcomes are reported via incremental cost-effectiveness ratios (ICER, benefit expressed as QALYs). Results: For all patients the ICER for all patients was £32,180/ QALY (Δ QALYs:2.04, Δ Costs:£64,629). In patients with del 17p/TP53 mutations the ICER was £19,040/QALY (Δ QALYs:4.39, Δ Costs:£83,636). The results were sensitive to changes in OR rates and utility values. In particular, the ICERs fell below £30,000/QALY if utility values from previous UK HTAs of treatments for CLL were used. The ICERs were robust to changes in adverse event rates/costs and alterations to background resource use patterns. cOnclusiOns: IR is likely to be a cost-effective intervention in all CLL patients for which it has achieved European marketing approval. 
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